• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BCAX

    Bicara Therapeutics Inc.

    Subscribe to $BCAX
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for Bicara Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    5/23/2025$8.00Underweight → Equal Weight
    Wells Fargo
    4/17/2025$8.00Underweight
    Wells Fargo
    2/6/2025$31.00Outperform
    Wedbush
    12/6/2024$42.00Buy
    H.C. Wainwright
    11/5/2024$48.00Buy
    Rodman & Renshaw
    10/8/2024Overweight
    Cantor Fitzgerald
    10/8/2024$35.00Overweight
    Morgan Stanley
    10/8/2024Buy
    TD Cowen
    10/8/2024$47.00Buy
    Stifel
    See more ratings

    Bicara Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Possible Members of 10% Group Flynn James E converted options into 1,725,174 shares and bought $1,260,000 worth of shares (70,000 units at $18.00) (SEC Form 4)

      4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

      9/17/24 6:16:55 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care